Sacubitril/valsartan ameliorates tubulointerstitial fibrosis by restoring mitochondrial homeostasis in diabetic kidney disease.

"Declarations Ethics approval and consent to participateAll experimental protocols were approved by the Ethics Committee of Affiliated Hospital of Qingdao University (No: QYFY WZLL 28034). Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding This work was supported by the National Natural Science Foundation of China (82000648); the Outstanding Youth Cultivation Foundation of Southeast University (2021ZDYYYQPY07), the Fundamental Research Funds for the Central Universities (2242023K40046), the Innovative and Entrepreneurial Talent (Doctor) of Jiangsu Province, the Natural Science Foundation of Shandong Province (ZR2022MH161), the Qingdao Medical and Health Research Program Project (2021-WJZD189), the Qingdao Key Health Discipline Development Fund, and the Qingdao Key Clinical Specialty Elite Discipline."